Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EPS (Weighted Average and Diluted) (2022 - 2026)

Indivior Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at $0.69 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) rose 81.58% year-over-year to $0.69; the TTM value through Mar 2026 reached $1.95, up 9850.0%, while the annual FY2025 figure was $1.64, 3180.0% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was $0.69 at Indivior Pharmaceuticals, down from $0.79 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $232258.1 in Q1 2023 and troughed at -$231632.7 in Q3 2023.
  • A 5-year average of $20715.6 and a median of $0.42 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 407.69% in 2023 and later surged 393.75% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$2.37 in 2022, then surged by 120.97% to $0.5 in 2023, then tumbled by 67.76% to $0.16 in 2024, then surged by 393.75% to $0.79 in 2025, then fell by 12.66% to $0.69 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for INDV at $0.69 in Q1 2026, $0.79 in Q4 2025, and $0.33 in Q3 2025.